share_log

BMO Capital Maintains Outperform on Acrivon Therapeutics, Raises Price Target to $25

BMO Capital Maintains Outperform on Acrivon Therapeutics, Raises Price Target to $25

BMO Capital维持Acrivon Therapeutics的跑赢大盘,将目标股价上调至25美元
Benzinga ·  04/26 14:01

BMO Capital analyst Etzer Darout maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and raises the price target from $18 to $25.

BMO Capital分析师埃策·达鲁特维持Acrivon Therapeutics(纳斯达克股票代码:ACRV)的跑赢大盘,并将目标股价从18美元上调至25美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发